July 29th 2025
Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Nina Chavez: OCM Has Made Community Oncologists Better Business People
Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM
Dr James Hamrick Discusses Bringing Value to Patients Through Engagement